Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.